Gujarat Themis shares jump 10% on €158 million Sanofi anti-TB portfolio deal
Mumbai-based Gujarat Themis Biosyn Ltd. (GTBL) has informed exchanges that it has signed an asset purchase agreement with Sanofi to acquire a portfolio of anti-tuberculosis (TB) and anti-infective brands, along with associated trademark and commercial rights. The deal, valued at €158 million, includes 13 established branded generic products with a presence across more than 55…
